DDInter1313 DDInter1376
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Norfloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP1A1
Norfloxacin {u} (Compound) upregulates {v} (Gene) GHR
Norfloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Norfloxacin {u} (Compound) downregulates {v} (Gene) PRR7
Norfloxacin {u} (Compound) causes {v} (Side Effect) Paraesthesia
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ifosfamide
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Norfloxacin (Compound) resembles Gemifloxacin (Compound)
Norfloxacin (Compound) binds CYP1A1 (Gene)
Norfloxacin (Compound) upregulates GHR (Gene)
Norfloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Norfloxacin (Compound) downregulates PRR7 (Gene)
Norfloxacin (Compound) causes Paraesthesia (Side Effect)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix